Free Newsletter
Medtronic recall spawns inquiry
Little did Medtronic know that it would touch off a Congressional investigation when it recalled a key defibrillator component last week. The Committee on Oversight and Government Reform now is reviewing the FDA's procedures for approving heart-device components.
Committee Chairman Henry Waxman, a longtime U.S. Representative from California, is asking the agency for information on testing procedures for defibrillator leads. Meanwhile, the FDA said it would conduct its own internal review on whether to require lab testing before these products hit the market.
- check out the article from the New York Times
Related Articles:
Did patient lawsuit spur Medtronic recall? Report
Medtronic withdraws defibrillator part. Report
FDA panel: Approve Medtronic stent. Report
Medtronic's fortunes depend on new stent. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: